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ABSTRACT 
This study evaluates the genotoxic potential of two Ru(III) complexes with thiosemicarbazone based ligands. The 
complexes were tested for in vitro protective effect on chromosome aberrations in peripheral human lymphocytes 
using the cytokinesis block micronucleus (CBMN) assay at concentrations 1.5; 3.7 and 7.4 µg/mL. The cell culture 
treated with the tested complexes, at 3.7 µg/mL concentration, decreased a frequency of micronucleus for 37% and 
32%, when compared with the control cell cultures. At concentration of 7.4 (1.5) µg/mL of this complexes exhibited 
slightly lower effect of micronucleus for 30% (35%) and 27% (29%), when compared with the control cell cultures. 
Keywords: Ruthenium(III) complexes, Thiosemycarbazone, Chromosome aberrations, Genotoxicity, CBMN 
assay, Micronucleus 
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INTRODUCTION 
Metal complexes stay a significant resource for creating chemical diversity in the fields of biological, 
pharmaceutical and medicinal chemistry as antitumor and antimicrobial agents1-3. For this purpose, a large 
number of these complexes are synthesized and intensively investigated4-6. In the pre-clinical studies, the 
biological properties of the potential drug should be thoroughly investigated in order to obtain as much 
information as possible about its therapeutic and undesirable effects in the living organism7. 
Thiosemicarbazone and their metal complexes are of huge importance as they possess an abundant variety 
of biological properties including antibacterial, antifungal, antitumor, antiviral, anti malarial activities8-13. 
The chemistry and pharmacological applications of ruthenium thiosemicarbazone complexes have been 
extensively studied14-19. The complexes of Ru(III) with thiosemicarbazone based ligands exhibited in vitro 
antitumor activity against MCF-7 tumor cells, significant antiproliferative activities on human 
lymphocyte culture and inhibitory effects on lung carcinoma A549 cells20,21. The synthesis of ruthenium 
dibasic tridentate thiosemicarbazones complexes with ONS donors are of great significance because of 
their wide range of medicinal activities22.  
The analysis of micronuclei (MN) in cultured lymphocytes is increasingly applied as a method to 
biomonitor human exposure to genotoxic agents, largely because the cytokinesis block (CB) technique, 
has made it possible to identify cells that have divided once in culture (second cycle interphase cells23. 
Micronuclei result from lesions/adducts at the level of DNA or chromosomes, or at the level of proteins 
directly or indirectly involved in chromosome segregation (e.g. tubulin). Formation of micronuclei 
originating from chromosome fragments or chromosome loss events requires a mitotic or meiotic 
 
  Vol. 11 | No. 2 |647 - 652 | April - June | 2018 
648 
CYTOKINESIS BLOCK MICRONUCLEUS                                                                                                                                N. Ljubijankić et al. 
division. The simplicity of scoring and the wide applicability of the in vitro micronucleus test in different 
cell types make it an attractive tool to assess cytogenetic abnormality23. Micronuclei are efficiently 
expressed in dividing cells when chromosome breaks are induced by peroxyl radicals. The induced 
chromosome breaks lag behind at anaphase in dividing cells and are subsequently packaged within 
nuclear membranes to produce micronucleus. Micronucleus (MN) expression in peripheral blood 
lymphocytes is well established as a method to monitor chromosome damage in human populations. The 
analysis of MN in cultured lymphocytes is increasingly applied as a method to biomonitor human 
exposure to genotoxic agents largely because the cytokinesis block (CBMN) technique has made it 
possible to identify cells that have divided once in culture (second cycle interphase cells) 24. 
In our previous paper, we showed synthesis and characterization of the Ru(III) complexes of the type 
Na[RuL2] (where L = dibasic tridentate thiosemicarbazone ligand) 14. The present article is a continuation 
of the research activities of the study on in vitro effects of these complexes on human lymphocytes using 
the CBMN assay. 
EXPERIMENTAL 
Synthesis of Ligands and Complexes 
Thiosemicarbazone ligands and complexes were prepared according to the previously published 
procedures14.5-Cl-salicylaldehyde thiosemicarbazone and 5-Br-salicylaldehyde thiosemicarbazone, 
hereinafter 5-X-SALTSC (X = Cl, Br) were prepared in reaction of thiosemicarbazide and 5-X-
salicylaldehyde (X = Cl, Br) in the molar ratio 1:1 in absolute ethanol. Complexes of Ru(III) with 
thiosemicarbazone ligands, hereinafter Na[Ru(5-X-SALTSC-2H)2] (where X = Cl, Br) were prepared in 
reaction of appropriate thiosemicarbazone ligand and RuCl3 in the molar ratio 2:1 in absolute ethanol.  
 
Subjects 
Venous blood samples were obtained using heparinized sterile vacutainers (Becton Dickinson, Bradford, 
MA) from five healthy non/smoking female volunteers who had not been exposed to chemicals, drugs or 
other substances. 
A safety protocol concerning blood/born pathogen/biohazard was taken. The volunteers gave their 
permission for using their blood for the experiment. From each subject, two aliquots of blood, 5mL each 
were obtained. The study complied with the code of ethics of the World Medical Association (Helsinki 
Declaration of 1964, as revised in 2002)25. The blood samples were obtained at the Medical Unit in 
accordance with current Health and Ethical regulations in Serbia, Law on Health Care (2005)26. 
 
Cytokinesis-block MN assay 
The culture lymphocytes were treated with tested complexes (1.5; 3.7, and 7.4 µg/mL). One cell culture 
served as the control and isolated complexes were not added in this. One cell culture containing 
Amifostine WR-2721(98%, S-2[3-aminopropylamino]-ethylphosphothioic acid) at 1.0 µg/mL), 
(Marligen-Biosciences,USA), was used as a positive control. They were added to the cultures 25 h after 
phytohaemaglutinin (PHA) stimulation and life until harvest. All cultures were incubated in a thermostat 
at 37°C. Treatment with the investigated complexes lasted for 19 h, where after all cultures were rinsed 
with a pure medium, transferred into 5 mL fresh RPMI 1640 medium (RPMI 1640 Medium + GlutaMAX 
+ 25 mM HEPES; Invitrogen-Gibco-BRL, Vienna, Austria) and incubated for additional 72 h. 
Approximately 2 x 106 blood lymphocytes were set up in 5 mL RPMI-1640 medium supplemented with 
15% of calf serum and 2.4 µg/mL of phytohaemaglutinin (Invitrogen-Gibco- BRL). One hour after 
initiating the cell stimulation, investigated complexes (three concentrations) were added to the samples. 
The incidence of spontaneously occurring MN in control samples was scored. For MN preparation, the 
cytokinesis-block method of Fenech and Morley was used with some modifications, as described in 
Stankovic et al. 23,27. At least 1000 binucleated (BN) cells per sample were scored, registering MN 
according to the criteria of Countryman and Heddle, and Fenech and Morley28,23. Cytochalasin B 
(Invitrogen-Gibco-BRL, Vienna, Austria) at a final concentration of 6 µg/mL was added to the samples 
after 44 h of culture, and the lymphocyte cultures were incubated for a further 24 h. After 72 h of culture, 
the cells were washed with 0.9% NaCl (Merck, Sharp and Dohme GMBH., Vienna, Austria), collected by 
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centrifugation and treated with a hypotonic solution at 37°C. The hypotonic solution consisted of 0.56% 
KCl + 0.9% NaCl (mixed in equal volumes). The cell suspension was prefixed in methanol/acetic acid 
(3:1), washed three times with fixative, and dropped onto a clean slide23. The slides were air dried and 
stained with alkaline Giemsa 2% (Sigma-Aldrich, Vienna, Austria). At least 1000 binucleated (BN) cells 
per sample were scored, registering MN according to the criteria of Countryman and Heddle and Fenech 
and Morley28,23. The effects of investigated complexes on cell proliferation were estimated by the 
cytokinesis-block proliferation index (CBPI), calculated as suggested by Surralles and others29. CBPI = 
[(MI + 2MII + 3(MIII + MIV)]/N, where M I-IV represent the number of cells with 1 to 4 nuclei, 
respectively, and M is the number of cells scored. For the analysis of MN, only binucleated cells with 
well-preserved cytoplasm were scored (under a light microscope with a 40 × 10 magnification). The 
criteria for selection of binucleated cells and identification of MN given in the HUMAN project website 
(http://www.humn.org) were followed25. The number of binucleated cells with 1, 2, 3 or more MN was 
then tabulated. The data for each treatment were expressed as the frequency of MN per 1000 binucleated 
cells. 
 
Statistics and index calculation 
The statistical analysis was performed using Origin software package version 7.0. The statistical 
significance of the difference between the data pairs was evaluated by analysis of variance (One way 
ANOVA) followed by the Tukey test. Statistical difference was considered significant at p< 0.01 and p< 
0.05. The index calculating is presented as the % of change comparing different groups. 
 
RESULTS AND DISCUSSION 
The structures of tested Ru(III) thiosemicarbazone complexes are shown in Fig.-1.  
 
 
 
Fig.-1: The structure of Na[Ru(5-X-SALTSC-2H)2] (where X = Cl, Br) 
 
The results of Cytokinesis –Block Micronucleus (CBMN) 
This article summarized the results of using CBMN assay to evaluate the antioxidant potential of 
complexes in human lymphocytes. They were associated with DNA repair system inhibitor, aminofostine 
WR-2721. The complexes were tested for in vitro protective effect on chromosome aberrations in 
peripheral human lymphocytes using CBMN assay at concentrations of 1.5; 3.7 and 7.4 µg/mL. The 
frequencies and distribution of MN in human lymphocytes were scored. The results are presented in 
Table-1. 
The cell culture treated with the tested complex Na[Ru(5-Br-SALTSC -2H)2] at a concentration of 3.7 
µg/mL, exhibit the decreasing the significant (p < 0.01), frequency of MN by 37%, when compared with 
the control cell cultures. Concentration of 1.5 and 7.4 µg/mL of this complex exhibited slightly lower 
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effect (35% and 30%; p<0.01 and p < 0.05). The complex Na[Ru(5-Cl-SALTSC-2H)2] at a concentration 
of 3.7 µg/mL also caused significant (p < 0.05), decrease of the MN frequency (32%), but less than 
former doses, when compared with the control cell cultures. The concentration of 1.5 and 7.4 µg/mL of 
this complex exhibited decreasing the significant (p<0.05) frequency of MN by (29% and 27%) when 
compared with the control cell cultures. 
 
Table-1: Incidence of  MN, cytokinesis-block proliferation index, distribution MN per cells and frequency of MN, 
measurement in cell cultures of human lymphocytes treated with different concentration of complexes 
Conc. 
µg/mL 
MN/1000 
Bn cell 
% Bn cell 
with MN 
MN/Bn 
Cell CBPI 
Frequency 
of MN 
Control 24.00 ± 1.82 1.91 ± 0.17 1.26 ± 0,05 1.64 ± 0,03 100,00 % 
Amifos. -1.0 
µg/mL 19.69 ± 0.85 1.56 ± 0.10 1.27 ± 0,05 1.97 ± 0,03 82,04 % 
Na[Ru(5-Cl-
SALTSC-2H)2] 
1.5 µg/mL 
17.16 ± 0.46  a*,b* 1.52 ± 0.05 1.16 ± 0,04 1.68 ± 0,04 71,5 % 
Na[Ru(5-Cl-
SALTSC-2H)2] 
3.7 µg/mL 
16.40 ± 1.60 a* 1.34 ± 0.17 1.23 ± 0,06 1.62 ± 0,03 68,3 % 
Na[Ru(5-Cl-
SALTSC-2H)2] 
7.4 µg/mL 
17.64 ± 0.52 a* 1.52 ± 0.05 1.16 ± 0,04 1.68 ± 0,04 73,5 % 
Na[Ru(5-Br-
SALTSC-2H)2] 
1.5 µg/mL 
15.59 ± 1.22 a,b* 1.26 ± 0.11 1.24 ± 0,05 1.66 ± 0,05 65,0% 
Na[Ru(5-Br-
SALTSC-2H)2] 
3.7 µg/mL 
15.20 ± 2.58 a 1.37 ± 0.21 1.10 ± 0,04 1.68 ± 0,02 63,3 % 
Na[Ru(5-Br-
SALTSC-2H)2] 
7.4 µg/mL 
16.75 ± 1.07 a* 1.42 ± 0.12 1.15 ± 0,07 1.61 ± 0,02 69,8 % 
MN/1000 Bn cells - incidence of micronuclei in 1000 binucleated cells 
% Bn cells witch micronuclei 
MN/Bn cells - the incidence of micronuclei in binucleated cells. 
CBPI- cytokinesis-block proliferation index. 
The frequency of MN → incidence of MN presented as % from control groups in cell cultures of human 
lymphocytes treated with different concentration of complexes. The statistical significance of the difference 
between the data pairs was evaluated by analysis of variance (One-way ANOVA) followed by the Tukey test. 
Statistically, difference was considered significant at p<0. 
a Compared with control groups, statistically significant difference p < 0.01. 
a* Compared with control groups, statistically significant difference p < 0.05. 
b Compared with amifostine – WR 2721, statistically significant difference p < 0.01. 
b* Compared with amifostine – WR 2721, statistically significant difference p < 0.05. 
 
The frequency of MN is statistically significant (p < 0.05) between cell cultures treated with amifostine (1 
µg/mL) and cell cultures treated with complexes Na[Ru(5-Cl-SALTSC-2H)2] and Na[Ru(5-Br-SALTSC -
2H)2] (1.5 µg/mL). 
The effect of complexes on cell proliferation was investigated by determining the cytokinesis-block 
proliferation index (CBPI). Table-1, showed the mean CBPI values and standard errors calculated at 
different concentrations of complexes. The comparable CBPI values for complexes and aminofostine 
WR-2721 suggested an inhibitory effect on lymphocyte proliferation of tested complex. Since MN 
expression is dependent on cell division, quantification of cell proliferation and cell death should be 
assessed to obtain a sound evaluation of cell kinetics and MN frequencies. 
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In this study we found that the lower concentration of complexes possesses beneficial effect on 
lymphocyte cells culture by decreasing the frequency of MN. Our results provide the evidence of 
protective effects of tested complexes on cytogenetic and damages in human lymphocytes treated in vitro. 
 
CONCLUSION 
Two ruthenium(III) thiosemicarbazide complexes, Na[Ru(5-Cl-SALTSC-2H)2] and Na[Ru(5-Br-
SALTSC-2H)2], were tested for antioxidant potential in peripheral human lymphocytes using the CBMN 
assay. We found that complexes reduced the frequency of MN in concentration-dependent manner and 
the medium concentration of 3.7 µg/mL was the most effective. This result is important taking into 
account that synthetic protectors, used in the treatment of humans, decrease the frequency of MN by 
around 18% (Amifostin WR-2721)30. 
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